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Clinical trialsTo assess withdrawal-related adverse event (AE) rates following abrupt clobazam discontinuation in Phase I
trials and gradual clobazam tapering (2–3 weeks) following discontinuation from III trialsmet the criteria for po-
tential/III trials,we evaluatedAE data from fourmultiple-dosage Phase I trials (duration: 8–34 days). Therapeutic
(20 and 40 mg/day) and supratherapeutic clobazamdosages (120 and 160 mg/day)were administered. Adverse
events (AEs) were also assessed for patients with Lennox–Gastaut syndrome enrolled in Phase II (OV-1002) and
Phase III (OV-1012) studies (duration ≤ 15 weeks) and in the open-label extension (OLE) trial OV-1004
(≤5 years). Potential withdrawal-related AEswere identiﬁed by preferred terms, provided that the AEs occurred
≥1 day following and≤30 days after the last clobazam doses, or were deemed withdrawal symptoms by inves-
tigators. Clinical Institute Withdrawal Assessment for Benzodiazepines (CIWA-B) scale was used to evaluate
withdrawal intensity in three of the four Phase I trials. A total of 207 participants in Phase I trials received
steady-state clobazam dosages of 20–160 mg/day, 182 received clobazam dosages of ≥40 mg/day, and 94 re-
ceived clobazam dosages of ≥120 mg/day. Abrupt clobazam discontinuation led to 193 withdrawal-related
AEs for 68 Phase I participants. Nearly 50% of AEs occurred after discontinuation of clobazam dosages of
≥120 mg/day. Adverse events were mild or moderate and included headache (14% of Phase I participants), in-
somnia (12.6%), tremor (10.1%), and anxiety (8.7%). The CIWA-B scores varied (range: 0–59). Most scores
were b30, indicating possible mild benzodiazepine withdrawal. III trials met the criteria for potential/III patients
received clobazamdosages of≤40 mg/day, and those in theOLE trial received clobazamdosages of≤80 mg/day.
Eighty-seven patients discontinued clobazam and were gradually tapered. No withdrawal-related AEs or inci-
dences of status epilepticus were reported. Withdrawal-related AEs observed in Phase I studies following abrupt
clobazam discontinuation at therapeutic and supratherapeutic dosages were generally mild. No withdrawal-
related AEs occurred when dosages were tapered over 3 weeks, after short- or long-term clobazam use
(≤5 years).
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Lennox–Gastaut syndrome (LGS), a severe childhood epileptic en-
cephalopathy, is characterized by slow spike-and-wave electroenceph-
alograms, as well as by occurrence of several seizure types including
tonic, atonic, and atypical absence [1]. Most patients with LGS have
chronic, treatment-refractory epilepsy throughout childhood and ado-
lescence. Abnormal mental development and behavioral disturbancesorth, Deerﬁeld, IL 60015, USA.
. This is an open access article underare common in these patients, and most experience continued
neurocognitive impairment that persists into adulthood.
The 1,5-benzodiazepine clobazam (Onﬁ®)was approved in 2011 by
the US Food and Drug Administration as adjunctive treatment for
seizures associated with LGS for patients 2 years of age and older [2].
Efﬁcacy and safety of clobazam in patients with LGS have been
established in III trials met the criteria for potential/III trials [3–6]. Out-
side the United States, clobazam has been used to treat anxiety disor-
ders and epilepsy for several decades [2].
The abrupt discontinuation of benzodiazepines often results in a
spectrum of adverse events (AEs) related to withdrawal [7–9]. These
symptoms often include anxiety, insomnia, irritability, sedation,
seizures, and somnolence. To determine the potential withdrawal-the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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I trials (during which clobazam dosages were abruptly discontinued)
and III trials met the criteria for potential/III epilepsy trials (during
which clobazam dosages were tapered gradually).
2. Methods
Potentialwithdrawal-relatedAEs following abrupt clobazamdiscon-
tinuation in four Phase I trials or gradual tapering in three III trials met
the criteria for potential/III clobazam trials were assessed. The trials
are summarized below.
2.1. Phase I trials (abrupt clobazam discontinuation)
2.1.1. OV-1022
This thorough cardiac conduction (T-QT) study was double-blind,
double-dummy, randomized, single-site, 4-arm, and parallel-group in
design. The objective of this trial was to examine the potential
of clobazam and its primary active metabolite, N-desmethylclobazam
(N-CLB), to have clinically signiﬁcant effects on cardiac intervals at
both therapeutic (40 mg/day) and supratherapeutic (160 mg/day)
dosages compared with moxiﬂoxacin (400 mg/day, active control)
and placebo. The QT interval is the time between the start of the
Q-wave and the end of the T-wave on an EKG.
A total of 280 healthymale and female volunteers were enrolled and
divided among the four groups. Treatments were administered under
fasting conditions from Days 1 through 29 and discontinued abruptly
(no tapering of dosage).
2.1.2. OV-1023
This open-label, multiple-dosage, drug-interaction study assessed
the safety, tolerability, and single-dose pharmacokinetics (PK) proﬁles
of a drug cocktail containing midazolam (4 mg), caffeine (200 mg),
tolbutamide (500mg), and dextromethorphan (30mg), followingmul-
tiple clobazam dosages. The drug cocktail represents agents that are
substrates of certain cytochrome P450 isoenzymes.
A total of 18 healthy male volunteers were enrolled and admin-
istered the drug cocktail on the morning of Day 1. Oral clobazam
(40 mg) was then administered once daily on Days 4–18, and then a sin-
gle oral dose of clobazam (40 mg) was coadministered with a single oral
dose of the drug cocktail on Day 19 before treatment was discontinued.
2.1.3. OV-1032
The objective of this Phase 1, open-label, multiple-dosage study was
to examine the effects of impaired renal function (mild and moderate)
on the PK proﬁle of clobazam. Seven participants with mild and six
participants with moderate renal impairment (based on estimated
creatinine clearance [CLCR] N 50–80 mL/min and CLCR 30–50 mL/min,
respectively) and 12 control participants with normal renal function
(CLCR N 80 mL/min) were enrolled. Healthy participants were matched
to those with renal impairment at the same centers on the basis of age,
race, sex, weight, and smoking status. All participants received a single
20-mg dose of clobazam on Day 1 and once-daily clobazam on Days
5–11. Participants fasted overnight prior to study drug administration
each morning.
2.1.4. OV-1038
This open-label, single-center, multiple-ascending–dosage study
was designed to evaluate the safety, tolerability, and the steady-state
PK proﬁle of clobazam in healthy adult participants. Twenty-four partic-
ipants (male or female) were enrolled and assigned to one of two
treatment groups. Data from Group 1 were used to establish the maxi-
mum-tolerated-titrated dosage, deﬁned as the greatest dosage in excess
of 60-mg/day tolerated-titrated dosage that was tolerated for 3 consec-
utive days by at least 70% of the individuals who had previously tolerat-
ed 60-mg/day tolerated-titrated dosage.Studymedicationwas administered twice daily under fasting condi-
tions. In Group 1, clobazam was titrated from 10-mg/day tolerated-
titrated dosage to 160-mg/day tolerated-titrated dosage, with each
dosage administered for at least 3 days prior to dosage increase.
The tolerated-titrated dosage was increased by 10- mg/day through
60-mg/day tolerated-titrated dosage and then by 20 mg/day until ei-
ther 160-mg/day tolerated-titrated dosage was reached or the dosage
was deemed intolerable (which included, butwas not limited to, assess-
ment by scales and AEmonitoring) by investigators. Clobazamadminis-
tration was concluded with a single morning dose of the maximum
tolerated-titrated dosage (80 mg).
In Group 2, dosage titration was performed in a manner similar
to Group 1, with the greatest scheduled dosage of 140-mg/day
tolerated-titrated dosage. However, based on preliminary safety and
PK assumptions, the greatest dosage administered in Group 2 was
120-mg/day tolerated-titrated dosage. Once participants had been
titrated to 120-mg/day tolerated-titrated dosage and demonstrated tol-
erability for 3 days, they then received 120-mg/day tolerated-titrated
dosage for an additional 11 days, followed by a ﬁnal morning dose of
60 mg.
2.2. III trials met the criteria for potential/III trials (gradual clobazam
tapering)
In trials OV-1002, OV-1012, and OV-1004, patients who discontinued
were gradually tapered off clobazam.
2.2.1. OV-1002 and OV-1012
Trial OV-1002 was a Phase II, multicenter, randomized, double-
blind, dosage-ranging, parallel-group study designed to assess the efﬁ-
cacy and safety of clobazam as adjunctive therapy to a stable regimen
of antiepileptic drugs (AEDs) in patients 2–30 years of age with LGS
[3]. The study consisted of a 4-week baseline period, a 3-week titration
period, a 4-weekmaintenance period, and a 3-week taper period,with a
ﬁnal visit 1 week after last dose for patients not continuing in the open-
label extension (OLE) study OV-1004.
The Phase III OV-1012 trial (also known as CONTAIN4) was a multi-
center, randomized, double-blind, placebo-controlled study that
assessed the efﬁcacy and safety of clobazam as adjunctive therapy to a
stable AED regimen in patients 2–60 years of age with LGS [4]. The
study included a 4-week baseline period, a 3-week titration period,
and a 12-week maintenance period, followed by either continuation in
theOV-1004OLE or a 2- to 3-week taper period (depending on patients'
weights), with a follow-up visit 1 week after the last clobazam dose.
In trial OV-1002, patients were randomly assigned to low-dosage
clobazam (0.25 mg/kg up to a maximum daily dosage of 10 mg/day)
or high-dosage clobazam (1.0 mg/kg, up to a maximum daily dosage
of 40 mg/day). In trial OV-1012, patients were randomly assigned
to placebo, low-dosage clobazam (0.25 mg/kg/day, maximum daily
dosage of 10 mg/day), medium-dosage clobazam (0.5 mg/kg/day,
maximum daily dosage of 20 mg/day), or high-dosage clobazam
(1.0 mg/kg/day, maximum daily dosage of 40 mg/day). For both trials,
study medication was administered twice daily. During titration,
clobazam was initiated at either 5 mg/day or 10 mg/day. Dosages
were then increased every 7 days until assigned target dosages were
attained. Clobazam was administered twice daily. Investigators could
decrease daily clobazamdosages by a single tablet (placebo or clobazam
dosage of 5 mg/day) if a patient developed signs or symptoms of drug
intolerance. The minimum clobazam dosage was 5 mg/day.
2.2.2. OV-1004
Patients from trials OV-1002 and OV-1012 were given the option of
enrolling in OV-1004, a multicenter, OLE study of clobazam as adjunc-
tive therapy in patients with LGS [5,6]. The objective of this OLE trial
was to collect safety and efﬁcacy information regarding long-term
clobazam usage in patients with LGS.
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of clobazam 0.5 mg/kg. Clobazam was given twice daily and the maxi-
mum allowed daily dosage was 2.0 mg/kg/day (maximum daily dosage
of 80 mg/day). Investigators were allowed to initiate, adjust, and dis-
continue other AEDs and other forms of treatment to optimize patient
care. During the ﬁrst 4 weeks of the OLE trial, dosages were titrated to
efﬁcacy. Rescue medications were permitted no more than once
per month. Upon completion of treatment, patients either continued
commercially available clobazam or discontinued clobazam through a
maximum 3-week taper period.2.3. Analysis
2.3.1. Withdrawal-related adverse events
For the Phase I–III clobazam studies, potential withdrawal-related
AEs were identiﬁed in the clinical trial safety database if they met
the following criteria: 1) AE preferred term was in the potential
withdrawal-related search term list in the database (Table 1) and 2)
AE start date occurred at least 1 day following the last dose of clobazam
and within 30 days after the last dose of study drug, or the AE was
assigned by the principal investigator as a symptom of withdrawal.
Potential withdrawal-related AE data were obtained from III trials met
the criteria for potential/III studies from patients who had completed
or discontinued the trials.2.3.2. Clinical Institute Withdrawal Assessment for Benzodiazepines
(CIWA-B) scale
The CIWA-B scale (Appendix A) was administered before dosing,
during dosing, daily from the last day of dosing until the patient com-
pleted or discontinued the study and ad hoc at the investigators' discre-
tion during Phase I studies OV-1022, OV-1023, andOV-1038. The CIWA-
B scale evaluates benzodiazepine withdrawal using 20 ﬁve-point items
[10]. The ﬁrst three items (restlessness, tremor, and sweating) are eval-
uated by an observer, and the remaining 17 items are answered by the
patients. The CIWA-B scores range from 0 to 80; scores≤ 20 are indica-
tive of possible mild benzodiazepine withdrawal.3. Results
3.1. Discontinuations in multiple-dosage Phase I and III trials met the
criteria for potential/III trials
A total of 207 of 347 participants in the four Phase I studies received
multiple clobazam dosages (range: 20 to 160 mg/day) and were
abruptly discontinued from the drug (Table 2). None of the participants
who received moxiﬂoxacin or placebo were included in this analysis. In
the two double-blind III trials met the criteria for potential/III trials and
the OLE trial, 33 (13%) and 54 (20%) patients, respectively, discontinued
clobazam treatment. For all discontinuing patients in the III trials met
the criteria for potential/III trials, clobazam dosages were gradually ta-
pered over a maximum of 3 weeks.Table 1
List of preferred terms to identify potential withdrawal-related AEs.
Abdominal pain Hyperacusis Myalg
Agitation Photophobia Nervou
Confusional state Allodynia Hypoe
Delirium Hyperpathia Paresth
Depersonalization Sensory disturbance Restles
Derealization Abnormal dreams Hyper
Convulsion Irritability Psycho
Headache Mental impairment Tensio
a Reported terms were searched for any instance of the matching text string.3.2. Incidence of potential withdrawal-related adverse events in Phase I and
III trials met the criteria for potential/III studies
Of the 294 individuals whodiscontinued clobazam, 68 (32.9%) of the
207 participants in the Phase I trials experienced 193 potentially
withdrawal-related AEs (Table 3). No patients who discontinued from
the Phase II/III trials experienced potentially withdrawal-related AEs.
These AEs were mild or moderate, and the most commonly reported
events overall included headache (14.0%), insomnia (12.6%), tremor
(10.1%), and anxiety (8.7%). Moreover, no participants reported
withdrawal-related seizures. The majority of AEs (110 of 193, 57%)
were reported within 7 days after the last clobazam dose. Per protocol,
18 participants in trial OV-1022 (10 in the 40-mg/day tolerated-titrated
dosage group and 8 in the 160-mg/day tolerated-titrated dosage group)
and ﬁve participants in trial OV-1038 (3 in the 120-mg/day tolerated-
titrated dosage group and 2 in the 160-mg/day tolerated-titrated
dosage group) were treated with lorazepam and/or diazepam to
manage withdrawal symptoms. The onset of withdrawal-related AEs
following clobazam discontinuation treated with lorazepam and/or di-
azepam ranged from 2 to 19 days. Fifteen of the 193 AEs weremanaged
with concomitant medications such as acetaminophen, loperamide,
sleep aids, and propranolol. Status epilepticus was not observed follow-
ing patient discontinuation in the Phase II/III trials.
3.3. CIWA-B scale
Three Phase I trials included the CIWA-B scale as an outcome. In trial
OV-1022, the CIWA-B scores ranged from 0 to 56 (Fig. 1). Ten and 12
participants in the clobazam 40-mg/day tolerated-titrated dosage and
160-mg/day tolerated-titrated dosage groups, respectively, had CIWA-
B scores N 20. Further, ﬁve participants in the placebo group and six in
the moxiﬂoxacin group also had CIWA-B scores N 20. One participant
each in the 40-mg/day tolerated-titrated dosage and 160-mg/day toler-
ated-titrated dosage groups had CIWA-B scores N 40. Of these partici-
pants, two in the clobazam 40-mg/day tolerated-titrated dosage group
and one in the clobazam 160-mg/day tolerated-titrated dosage group
experienced AEs related to withdrawal.
Although withdrawal-related AEs were reported for four partici-
pants in trial OV-1023, only three had CIWA-B scores N 20 (maximum
value of 27) at any time during the study (Fig. 1). In trial OV-1038, of
participants who received clobazam120 mg/day, all but one participant
had CIWA-B scores ≤ 20. One participant had a CIWA-B score of 23 in
the clobazam 120-mg/day group. Of participants in the clobazam
160-mg/day group, only one participant had a CIWA-B score N 20 at
any time during the study. In addition, one participant had a CIWA-B
score of 59 in the clobazam 160-mg/day group.
For all three trials, no correlations between CIWA-B scores and
withdrawal-related AEs were observed.
4. Discussion
This article describes withdrawal-related AEs following abrupt
clobazam discontinuation (Phase I trials, 207 participants) and gradual









Potentially withdrawal-related adverse events following discontinuation of clobazam in multiple-dose Phase I studies and Phase II/III studies.
Study Number of discontinued clobazam
participants/total enrollment
Maximum-tolerated–titrated
dosage at end of study (mg/day)
Clobazam dosing duration
(including titration)
Potentially withdrawal AEs following
clobazam discontinuation
Number of participants Number of events
Phase I (abrupt discontinuation)
OV-1022 140/280 40a and 160a 21 days 23b and 29c 90b and 75c
OV-1023 18/18 40 29 days 4 8
OV-1032 25/25 20 16 days 2 2
OV-1038 24/24 120d and 160d 34 days 5e and 5c 9e and 9c
Phase II/III (gradual taper)
OV-1002 7/68 40 Up to 10 weeks 0 0
OV-1004 54f/267 80 Up to 5 years 0 0
OV-1012 26/179 40 Up to 18 weeks 0 0
AE = adverse event.
a 70 participants.
b 40-mg/day dosage group.
c 160-mg/day dosage group.
d 12 participants.
e 120-mg/day dosage group.
f Taper per protocol was assumed for all patients who discontinued.
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physicians caring for patients with LGS and other epilepsies.
Of all the data evaluated, only participants in the Phase I trials expe-
rienced potentially withdrawal-related AEs. Although multiple thera-
peutic and supratherapeutic clobazam dosages were administered in
these trials, the incidences of withdrawal-related AEs were similar.
The most commonly reported withdrawal-related AEs were consistent
with those observed following benzodiazepine discontinuation [7–9].
None of the events were severe, and all resolved. Notably, the 2- to 3-
week gradual tapering used in the Phase II/III trials was more rapid
than typical clinical practice, yet none of the patients who discontinued
the Phase II/III trials met the criteria for potentially withdrawal-related
AEs. The results show that gradual clobazam taperingmay lessen the po-
tential forwithdrawal-relatedAEs, as opposed to abrupt discontinuation.
The CIWA-B scale is used to evaluate the overall degree of benzodi-
azepine withdrawal symptoms. Given that 17 of the 20 questions used
to evaluate the CIWA-B scores are self-rated, score variability is likely.
Indeed, this was observed in the three Phase I clobazam trials presentedTable 3






Participants reporting ≥1 AE 52 (37.1) 4 (22.2)
Headache 23 (16.4) 0
Insomnia 25 (17.9) 0
Tremor 20 (14.3) 0
Anxiety 15 (10.7) 1 (5.6)
Palpitations 10 (7.1) 1 (5.6)
Decreased appetite 7 (5.0) 0
Diarrhea 4 (2.9) 0
Hyperhidrosis 7 (5.0) 0
Irritability 5 (3.6) 2 (11.1)
Restlessness 4 (2.9) 0
Vision blurred 4 (2.9) 0
Disturbance in attention 3 (2.1) 0
Drug withdrawal syndrome 0 0
Fatigue 3 (2.1) 0
Paresthesia 3 (2.1) 0
Affect lability 2 (1.4) 0
Asthenia 2 (1.4) 0
Dizziness 2 (1.4) 0
Feeling cold 2 (1.4) 0
Nightmare 2 (1.4) 0
Visual impairment 2 (1.4) 0
a A total of 140 of 280 enrolled participants in the OV-1022 trial received clobazam.in this article, for which the CIWA-B scores ranged from 0 to 59. Partic-
ipantswith scores≤ 20 are considered to have possiblemild benzodiaz-
epine withdrawal. Although scores ranged from 0 to 56 in the placebo-
controlled trial OV-1022, a handful of clobazam-treated participants
had CIWA-B scores N 20. Furthermore, the numbers of participants
with CIWA-B scores N 20 in both the therapeutic and supratherapeutic
clobazam dosage groups were similar to scores for those participants
who did not receive clobazam. The greatest CIWA-B score in all three
trials (59) was reported in trial OV-1038 by one participant at a single
study visit. All other CIWA-B scores evaluated for this participant were
≤20. Despite the absence of a trend or correlation between these scores
and withdrawal-related AEs, the CIWA-B scores were useful in deter-
mining the intensity of withdrawal-related AEs in the three Phase I
trials. To counter the variability in the CIWA-B scores, the questionnaire
was and should be administered at several time points to evaluate
withdrawal following benzodiazepine discontinuation.
Two benzodiazepine drugs are approved in the United States for







2 (8.0) 10 (41.7) 68 (32.9)
0 6 (25.0) 29 (14.0)
0 1 (4.2) 26 (12.6)
0 1 (4.2) 21 (10.1)
0 3 (12.5) 18 (8.7)
0 0 11 (5.3)
0 0 7 (3.4)
2 (8.0) 1 (4.2) 7 (3.4)
0 0 7 (3.4)
0 0 7 (3.4)
0 1 (4.2) 5 (2.4)
0 0 4 (1.9)
0 0 3 (1.4)
0 3 (12.5) 3 (1.4)
0 0 3 (1.4)
0 0 3 (1.4)
0 0 2 (1.0)
0 0 2 (1.0)
0 0 2 (1.0)
0 0 2 (1.0)
0 0 2 (1.0)
0 0 2 (1.0)
Fig. 1. CIWA-B score ranges after abrupt clobazam discontinuation in Phase I studies.
N-values represent the number of clobazam-treated participants in each study. Bars rep-
resentminimumandmaximumCIWA-B scores in each study. For OV-1022, therewere 22
participants with scores N20. Of those 22, 3 had scores N40. For OV-1023, 3 participants
had scores N20 (maximum value of 27). For OV-1038, there were 2 participants
with scores N20. One participant had a score of 23 and the other had a score of 59. In
OV-1022, 6 participants in themoxiﬂoxacin group had scores N20. Of these 6, 2 had scores
greater than 40. In the placebo group, 5 participants had scores N20, ofwhich 1 participant
had a score N40.
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used in treatment regimens for chronic epilepsy [12], the risk of with-
drawal seizures may make cessation of clonazepam therapy difﬁcult
and may necessitate use of special epilepsy care units [13].
There have been few reports of seizure exacerbation with clobazam
treatment. One was a case report of a single adult patient who devel-
oped negative myoclonic status after withdrawal of clobazam over
6 days [14]. While it is recommended that clobazam be tapered, there
may be situations in which inadvertent abrupt clobazam discontinua-
tion can occur. For example, studies have demonstrated that up to 30%
of children do not adhere to their AED regimens [15,16]. In the clobazam
OV-1012 study [4], clobazam was abruptly discontinued over 9 days
for one patient as a result of poor compliance. Gastroenteritis, as well
as surgical and other procedures, may render oral medications
implausible. Finally, serious AEs may require abrupt termination of the
medication.
Alongwith the established long-termefﬁcacy and safety of clobazam
for LGS over more than 5 years of therapy [6], the lack of severe
withdrawal-related events, including seizures, even in patients abruptly
withdrawn from dosages as great as 160 mg/day, and the absence of
any withdrawal-related AEs in patients with epilepsy tapered over a
maximum period of 3 weeks support the use of clobazam as chronic
therapy for LGS.
Although these results suggest that clobazam has mild withdrawal
effects following discontinuation, limitations exist in the overall
interpretation of the data. Primarily, the trials were not prospectively
designed to assesswithdrawal-related AEs following abrupt discontinu-
ation and gradual tapering in similar participant populations. To this
point, the Phase I trials consisted of healthy participants, and the
Phase II/III trials consisted of patients with LGS. In addition, the results
may have been confounded by the close degree of medical monitoring
in the setting of a clinical trial, which may over-represent the preva-
lence and severity of AEs that might be expected after clobazam discon-
tinuation in the clinic. Finally, the potential effects that different
durations of clobazam therapymay have had on incidence of potentially
withdrawal-related AEs are not clear.
In conclusion, the withdrawal-related AEs observed in the Phase I
studies following abrupt clobazam discontinuation were generally
mild and comparable those observed for other benzodiazepines. Nota-
bly, no withdrawal-related AEs occurred over the 2- to 3-week period
during which clobazam dosages were gradually tapered in the Phase
II/III studies, which is rapid in comparison with common clinical prac-
tice. In the OLE trial, no withdrawal-related AEs have been observedwhen dosages of clobazam were tapered over 3 weeks, after short- or
long-term clobazam use (≤5 years). Data from the Phase I–III studies,
including long-term open-label use, and supporting data from legacy
psychiatry studies, suggest that clobazam withdrawal-related AEs can
readily be avoided with gradual tapering of dosage.
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